12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Dyax, Novellus Biopharma AG sales and marketing update

Dyax and Novellus partnered to develop and commercialize Kalbitor ecallantide in select regions in Latin America to treat hereditary angioedema (HAE) and other angioedema indications. Novellus will have rights...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >